Chronic myeloid leukemia (CML) can be effectively treated inhibiting the disease-causing BCR::ABL1 kinase by tyrosine kinase inhibitors (TKIs). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.